Arrowhead Pharmaceuticals (ARWR) Current Deferred Revenue (2011 - 2026)

Arrowhead Pharmaceuticals' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $108.5 million for Q1 2026.

• Quarterly Current Deferred Revenue rose 150.86% year-over-year to $108.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.5 million (up 150.86% YoY) and the FY2025 annual result came in at $2.4 million, changed N/A from the prior year.
• Current Deferred Revenue was $108.5 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $111.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $130.0 million in Q3 2022 and bottomed at $866000.0 in Q3 2023.
• A 4-year average of $59.7 million and a median of $54.8 million in 2022 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue slumped 99.33% — and 2026, when it jumped 150.86%.
• Arrowhead Pharmaceuticals' Current Deferred Revenue stood at $66.3 million in 2022, then plunged by 98.69% to $866000.0 in 2023, then jumped by 12825.29% to $111.9 million in 2025, then decreased by 3.03% to $108.5 million in 2026.
• Business Quant data shows ARWR's Current Deferred Revenue at $108.5 million in Q1 2026, $111.9 million in Q4 2025, and $2.4 million in Q3 2025.